PEG-liposomal doxorubicin (PLD) at 40mg/m2 versus 50mg/m2 every month for patients with metastatic breast cancer: A comparative analysis of two prospective phase II studies

700 Background: Safety and tolerability are main objectives in the treatment of patients with advanced breast cancer (MBC). In randomized studies, PLD has demonstrated equivalent efficacy and less ...